Status:
NOT_YET_RECRUITING
Methoxyflurane for Analgesia During Hysteroscopy
Lead Sponsor:
Dr. John A. Thiel Medical Professional Corporation
Conditions:
Analgesia
Eligibility:
FEMALE
25-75 years
Phase:
NA
Brief Summary
This study is to assess the non-inferiority of using inhaled methoxyflurane (MOF) versus intravenous conscious sedation with fentanyl and midazolam on women's perception of pain, during hysteroscopy a...
Detailed Description
Methoxyflurane (MOF) is a halogenated hydrocarbon volatile general anesthetic that was discontinued in the 1960s due to potential nephrotoxicity. It was subsequently found that at sub-anesthetic doses...
Eligibility Criteria
Inclusion
- Abnormal uterine Bleeding requiring hysteroscopy Postmenopausal bleeding requiring hysteroscopy
Exclusion
- Uterine or patient characteristics that preclude hysteroscopy Submucosal fibroids requiring myomectomy Past allergic reaction to fentanyl or midazolam BMI \> 42 Contraindications precluding use of intravenous sedation (sleep apnea) Lack of patient consent History of malignant hyperthermia History of significant renal or hepatic disease
Key Trial Info
Start Date :
June 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 30 2026
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT06899724
Start Date
June 1 2025
End Date
January 30 2026
Last Update
March 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Saskatchewan
Saskatoon, Saskatchewan, Canada, S7N 0W0